| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Total income | 0.0 | 1.2 | 0.7 |
| Net profit | -0.2 | -0.0 | -0.0 |
| Operating margin | 0.0% | -0.0% | -0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: ROSELABS. Figures extracted from the filing.
Roselabs Finance Ltd: key numbers
- Share price
- ₹21.48
- Market cap
- ₹21.48 Cr
- Revenue (annual)
- ₹1.21 Cr
- Net profit (annual)
- ₹-0.31 Cr
- P/E (TTM)
- -68.2×Sector 34.6×
- Promoter holding
- 74.25%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Roselabs Finance Ltd
All →Roselabs Finance Acquisition
Roselabs Finance Ltd has issued a notice for an NCLT-convened meeting of equity shareholders on October 09, 2026, to consider the proposed Scheme of Merger by Absorption.
Roselabs Finance Annual General Meeting
Roselabs Finance Limited concluded its 32nd AGM on August 27, 2026. Shareholders approved all resolutions, including the re-appointment of Mr. Raghava Reddy Balineni as Managing Director.
Roselabs Finance Annual General Meeting
Roselabs Finance Limited has issued the notice for its 32nd Annual General Meeting scheduled for August 27, 2026. The meeting will address statutory appointments and standard business items.
Roselabs Finance Q1 FY27 Results: Net Loss of ₹0.1 Cr
Roselabs Finance Ltd reported a net loss of ₹0.1 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.1 Cr
Roselabs Finance Other Announcement
Roselabs Finance Ltd filed its shareholding pattern for the quarter ended June 30 2026. The filing details holdings of promoters, promoters group, public shareholders and institutions.
Roselabs Finance Board Meeting Date
Roselabs Finance Ltd will hold a board meeting on July 17, 2026 to approve its financial results. The trading window is closed from July 1 until 48 hours post‑results.